company background image
1228

CANbridge Pharmaceuticals SEHK:1228 Stock Report

Last Price

HK$1.38

Market Cap

HK$585.7m

7D

-6.1%

1Y

-52.4%

Updated

23 Sep, 2023

Data

Company Financials +

CANbridge Pharmaceuticals Inc.

SEHK:1228 Stock Report

Mkt Cap: HK$585.7m

1228 Stock Overview

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide.

1228 fundamental analysis
Snowflake Score
Valuation3/6
Future Growth2/6
Past Performance0/6
Financial Health3/6
Dividends0/6

CANbridge Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for CANbridge Pharmaceuticals
Historical stock prices
Current Share PriceHK$1.38
52 Week HighHK$3.20
52 Week LowHK$1.30
Beta0
1 Month Change-14.29%
3 Month Change-16.87%
1 Year Change-52.41%
3 Year Changen/a
5 Year Changen/a
Change since IPO-84.49%

Recent News & Updates

Recent updates

CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

May 05
CANbridge Pharmaceuticals Inc.'s (HKG:1228) 26% Dip In Price Shows Sentiment Is Matching Earnings

Shareholder Returns

1228HK BiotechsHK Market
7D-6.1%-0.8%-0.2%
1Y-52.4%6.4%1.0%

Return vs Industry: 1228 underperformed the Hong Kong Biotechs industry which returned 6.4% over the past year.

Return vs Market: 1228 underperformed the Hong Kong Market which returned 1% over the past year.

Price Volatility

Is 1228's price volatile compared to industry and market?
1228 volatility
1228 Average Weekly Movement6.6%
Biotechs Industry Average Movement8.0%
Market Average Movement6.5%
10% most volatile stocks in HK Market14.2%
10% least volatile stocks in HK Market3.2%

Stable Share Price: 1228 is not significantly more volatile than the rest of Hong Kong stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: 1228's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012118James Qun Xuehttps://www.canbridgepharma.com

CANbridge Pharmaceuticals Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare diseases and oncology indications worldwide. The company offers Hunterase, an enzyme replacement therapy for the treatment of Hunter syndrome; NERLYNX (Neratinlib), a potent irreversible tyrosine kinase inhibitor for HER2-positive breast cancer; and Caphosol Mouth Rinse for temporary and persistent dryness of the mouth and throat. It also engages in the development of CAN008, a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L; CAN108, an orally administered small molecule ASBT inhibitor; CAN106, a recombinant human monoclonal antibody that specifically binds to and neutralizes C5 in the complement system; CAN103, a recombinant human enzyme replacement therapy (ERT); CAN107, a fibroblast growth factor 23 (FGF23) blocking antibody; CAN104, a recombinant human ERT; CAN105, a bispecific antibody; CAN201, a gene therapy program that utilizes adeno-associated virus (AAV) sL65 capsid; and CAN202, a gene therapy program utilizing AAV sL65 capsid.

CANbridge Pharmaceuticals Inc. Fundamentals Summary

How do CANbridge Pharmaceuticals's earnings and revenue compare to its market cap?
1228 fundamental statistics
Market CapHK$585.66m
Earnings (TTM)-HK$485.03m
Revenue (TTM)HK$93.54m

6.3x

P/S Ratio

-1.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
1228 income statement (TTM)
RevenueCN¥87.30m
Cost of RevenueCN¥33.89m
Gross ProfitCN¥53.40m
Other ExpensesCN¥506.03m
Earnings-CN¥452.62m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-1.07
Gross Margin61.18%
Net Profit Margin-518.50%
Debt/Equity Ratio28.1%

How did 1228 perform over the long term?

See historical performance and comparison